Who
Julius Knowles
Director
Company insider
Files Form 4 as: Director, Keros Therapeutics.
In numbers
- Trades disclosed
- 283
- Buys
- 1
- Sells
- 39
- Bought
- $25K
- Sold
- $28.8M
- Companies
- 1
- Companies where not an officer
- 1
- First trade
- 13 Apr 2020
- Last trade
- 4 Jun 2026
- Last filed
- 8 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 4 Jun 2026filed 8 Jun 2026 | KROS Keros TherapeuticsBiotechnology | SEC FORM 4 Sold | $28K2,625 at $10.73 | filing |
| 4 Jun 2026filed 8 Jun 2026 | KROS Keros TherapeuticsBiotechnology | SEC FORM 4 Sold | $28K2,625 at $10.73 | filing |
| 3 Jun 2026filed 5 Jun 2026 | KROS Keros TherapeuticsBiotechnology | SEC FORM 4 Code A | —7,142 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | KROS Keros Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,433 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | KROS Keros Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —7,433 at $0.00 | filing |
| 3 Jun 2026filed 5 Jun 2026 | KROS Keros TherapeuticsBiotechnology | SEC FORM 4 Code A | —7,142 at $0.00 | filing |
| 21 Nov 2025filed 18 Dec 2025 | KROS Keros TherapeuticsBiotechnology | SEC FORM 4 Code D | $3.4M191,527 at $17.75 | filing |
| 21 Nov 2025filed 18 Dec 2025 | KROS Keros TherapeuticsBiotechnology | SEC FORM 4 Code D | $2.3M130,494 at $17.75 | filing |
| 4 Jun 2025filed 6 Jun 2025 | KROS Keros Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,500 at $0.00 | filing |
| 4 Jun 2025filed 6 Jun 2025 | KROS Keros TherapeuticsBiotechnology | SEC FORM 4 Code A | —5,250 at $0.00 | filing |
| 30 May 2024filed 3 Jun 2024 | KROS Keros Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 6 Jun 2023filed 8 Jun 2023 | KROS Keros Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 1 Jun 2022filed 3 Jun 2022 | KROS Keros Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,293 at $0.00 | filing |
| 5 Jan 2022filed 5 Jan 2022 | KROS Keros TherapeuticsBiotechnology | SEC FORM 4 Sold | $24K419 at $57.23 | filing |
| 5 Jan 2022filed 5 Jan 2022 | KROS Keros TherapeuticsBiotechnology | SEC FORM 4 Sold | $16K271 at $57.23 | filing |
| 5 Jan 2022filed 5 Jan 2022 | KROS Keros TherapeuticsBiotechnology | SEC FORM 4 Sold | $79K1,356 at $58.20 | filing |
| 5 Jan 2022filed 5 Jan 2022 | KROS Keros TherapeuticsBiotechnology | SEC FORM 4 Sold | $52K886 at $58.20 | filing |
| 5 Jan 2022filed 5 Jan 2022 | KROS Keros TherapeuticsBiotechnology | SEC FORM 4 Sold | $39K667 at $59.00 | filing |
| 5 Jan 2022filed 5 Jan 2022 | KROS Keros TherapeuticsBiotechnology | SEC FORM 4 Sold | $26K435 at $59.00 | filing |
| 4 Jan 2022filed 5 Jan 2022 | KROS Keros TherapeuticsBiotechnology | SEC FORM 4 Sold | $44K794 at $54.95 | filing |
News
Reviewing Upstream Bio (NASDAQ:UPB) and Keros Therapeutics (NASDAQ:KROS)KROS · themarketsdaily.com · 12 Oct 2026
0 headlines in the last 90 days name Julius Knowles; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.